Baird analyst Eric Coldwell raised the firm’s price target on Quest Diagnostics to $154 from $143 and keeps a Neutral rating on the shares. The analyst raised his estimates following management comments who’s emphasis was on partial capture of incremental tailwinds after reinvestment and inflationary uncertainty.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Doctors gain confidence in new Alzheimer’s blood tests, Bloomberg reports
- Quest Diagnostics price target raised to $165 from $160 at Mizuho
- Quest Diagnostics partners with Northern Light Health in Maine
- Quest Diagnostics awarded group purchasing agreement by Premier
- Quest Diagnostics Completes Acquisition of Outreach Lab Services Business of Summa Health